Anxiety Disorders and Depression Treatment Market 2027 by Drug, Therapies, Devices, Application, End User and Geography | The Insight Partners

Anxiety Disorders and Depression Treatment Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Antidepressant Drugs, Atypical Antipsychotics, Benzodiazepines, Beta-Blockers ); Therapies ( Electroconvulsive Therapy (ECT), Psychotherapy, Deep Brain Stimulation, Cognitive Behavior Therapy (CBT), Cranial Electrotherapy Stimulation (CES), Trans Cranial Magnetic Stimulation (TMS)); Devices (Cranial Electrotherapy Stimulator, fisher-wallace stimulator); Application (Phobia, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder, Major Depressive Disorder, other); End User (Hospitals, Mental Healthcare Centers, Other) and Geography

Report Code: TIPRE00008009 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

As per the Anxiety and Depression of America, approximately 322 million people are living with depression worldwide. Anxiety disorders are the most common mental disorders. However, they are treatable, and a number of treatments are available to help patients. Anxiety and depression are different conditions but mostly coexist. Nearly 50% of the population diagnosed with depression is also diagnosed with anxiety. These disorders cause people to avoid situations and trigger panic attacks.

MARKET DYNAMICS

The anxiety disorders and depression treatment market is anticipated to grow in the forecast period owing to the increasing prevalence of anxiety disorders and depression globally. Currently, developed countries are grappling with mental illnesses hugely. For instance, in the U.S., around 10 million people suffer from mental illness every year. This can be attributed to the increasing anxious millennial population in the region. Apart from this, increasing awareness and the growing contribution of government organizations to ease disease burden are further boosting the growth of the market. Some of the prominent organizations working in this space are the Hope for Depression, the National Alliance on Mental Illness, and the American Psychiatric Association, among others. In addition, an increase in research and development activities are opening new growth avenues for the market.

- For instance, in 2019, Johnson & Johnson received approval for its ketamine-based depression treatment
- Another notable advancement was the approval of first postpartum depression drug brexanolone by Sage Therapeutics in March 2019

MARKET SCOPE

The "Global Anxiety Disorders and Depression Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of anxiety disorders and depression treatment market with detailed market segmentation by drug type, therapies, devices, application, end user and geography. The global anxiety disorders and depression treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading anxiety disorders and depression treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global anxiety disorders and depression treatment market is segmented on the basis of drug class, therapies, devices, application and end users. Based on drug class, the market is segmented as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), antidepressant drugs, atypical antipsychotics, benzodiazepines, beta-blockers. Based on therapies, the market is segmented as electroconvulsive therapy (ECT), psychotherapy, deep brain stimulation, cognitive behavior therapy (CBT), cranial electrotherapy stimulation (CES), trans cranial magnetic stimulation (TMS). Based on devices, the market is segmented as cranial electrotherapy stimulator and fisher-wallace stimulator market. Based on application, the market is segmented into phobia, obsessive compulsive disorder (OCD), post-traumatic stress disorder, major depressive disorder and others. Based on end user, the market is segmented into hospitals, mental healthcare centers and others.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anxiety disorders and depression treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anxiety disorders and depression treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anxiety disorders and depression treatment market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anxiety disorders and depression treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the anxiety disorders and depression treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anxiety disorders and depression treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for anxiety disorders and depression treatment market in the global market. Below mentioned is the list of few companies engaged in the anxiety disorders and depression treatment market.

The report also includes the profiles of key anxiety disorders and depression treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Sumitomo Dainippon Pharma Co.
- Sage Therapeutics
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Abbott
- Sanofi
- H. Lundbeck A/S
- Johnson & Johnson

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anxiety Disorders And Depression Treatment Market - By Drug Class
1.3.2 Anxiety Disorders And Depression Treatment Market - By Therapies
1.3.3 Anxiety Disorders And Depression Treatment Market - By Devices
1.3.4 Anxiety Disorders And Depression Treatment Market - By Application
1.3.5 Anxiety Disorders And Depression Treatment Market - By End User
1.3.6 Anxiety Disorders And Depression Treatment Market - By Region
1.3.6.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. ANXIETY DISORDERS AND DEPRESSION TREATMENT - GLOBAL MARKET OVERVIEW
6.2. ANXIETY DISORDERS AND DEPRESSION TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 – DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
7.3.1. Overview
7.3.2. Selective Serotonin Reuptake Inhibitors (SSRIs) Market Forecast and Analysis
7.4. TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.4.1. Overview
7.4.2. Tricyclic Antidepressants (TCAs) Market Forecast and Analysis
7.5. MONOAMINE OXIDASE INHIBITORS (MAOIS)
7.5.1. Overview
7.5.2. Monoamine Oxidase Inhibitors (MAOIs) Market Forecast and Analysis
7.6. ANTIDEPRESSANT DRUGS
7.6.1. Overview
7.6.2. Antidepressant Drugs Market Forecast and Analysis
7.7. ATYPICAL ANTIPSYCHOTICS
7.7.1. Overview
7.7.2. Atypical Antipsychotics Market Forecast and Analysis
7.8. BENZODIAZEPINES
7.8.1. Overview
7.8.2. Benzodiazepines Market Forecast and Analysis
7.9. BETA-BLOCKERS
7.9.1. Overview
7.9.2. Beta-Blockers Market Forecast and Analysis

8. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 – THERAPIES
8.1. OVERVIEW
8.2. THERAPIES MARKET FORECASTS AND ANALYSIS
8.3. ELECTROCONVULSIVE THERAPY (ECT)
8.3.1. Overview
8.3.2. Electroconvulsive Therapy (ECT) Market Forecast and Analysis
8.4. PSYCHOTHERAPY
8.4.1. Overview
8.4.2. Psychotherapy Market Forecast and Analysis
8.5. DEEP BRAIN STIMULATION
8.5.1. Overview
8.5.2. Deep Brain Stimulation Market Forecast and Analysis
8.6. COGNITIVE BEHAVIOR THERAPY (CBT)
8.6.1. Overview
8.6.2. Cognitive Behavior Therapy (CBT) Market Forecast and Analysis
8.7. CRANIAL ELECTROTHERAPY STIMULATION (CES)
8.7.1. Overview
8.7.2. Cranial Electrotherapy Stimulation (CES) Market Forecast and Analysis
8.8. TRANS CRANIAL MAGNETIC STIMULATION (TMS)
8.8.1. Overview
8.8.2. Trans Cranial Magnetic Stimulation (TMS) Market Forecast and Analysis

9. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 – DEVICES
9.1. OVERVIEW
9.2. DEVICES MARKET FORECASTS AND ANALYSIS
9.3. CRANIAL ELECTROTHERAPY STIMULATOR
9.3.1. Overview
9.3.2. Cranial Electrotherapy Stimulator Market Forecast and Analysis
9.4. FISHER-AALLACE STIMULATOR
9.4.1. Overview
9.4.2. Fisher-Aallace Stimulator Market Forecast and Analysis

10. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 – APPLICATION
10.1. OVERVIEW
10.2. APPLICATION MARKET FORECASTS AND ANALYSIS
10.3. PHOBIA
10.3.1. Overview
10.3.2. Phobia Market Forecast and Analysis
10.4. OBSESSIVE COMPULSIVE DISORDER (OCD)
10.4.1. Overview
10.4.2. Obsessive Compulsive Disorder (OCD) Market Forecast and Analysis
10.5. POST-TRAUMATIC STRESS DISORDER
10.5.1. Overview
10.5.2. Post-Traumatic Stress Disorder Market Forecast and Analysis
10.6. MAJOR DEPRESSIVE DISORDER
10.6.1. Overview
10.6.2. Major Depressive Disorder Market Forecast and Analysis
10.7. OTHERS
10.7.1. Overview
10.7.2. Others Market Forecast and Analysis

11. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 – END USER
11.1. OVERVIEW
11.2. END USER MARKET FORECASTS AND ANALYSIS
11.3. HOSPITALS
11.3.1. Overview
11.3.2. Hospitals Market Forecast and Analysis
11.4. MENTAL HEALTHCARE CENTERS
11.4.1. Overview
11.4.2. Mental Healthcare Centers Market Forecast and Analysis
11.5. OTHERS
11.5.1. Overview
11.5.2. Others Market Forecast and Analysis

12. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET REVENUE AND FORECASTS TO 2027 – GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Anxiety Disorders And Depression Treatment Market Overview
12.1.2 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis
12.1.3 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Drug Class
12.1.4 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Therapies
12.1.5 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Devices
12.1.6 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Application
12.1.7 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By End User
12.1.8 North America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Countries
12.1.8.1 United States Anxiety Disorders And Depression Treatment Market
12.1.8.1.1 United States Anxiety Disorders And Depression Treatment Market by Drug Class
12.1.8.1.2 United States Anxiety Disorders And Depression Treatment Market by Therapies
12.1.8.1.3 United States Anxiety Disorders And Depression Treatment Market by Devices
12.1.8.1.4 United States Anxiety Disorders And Depression Treatment Market by Application
12.1.8.1.5 United States Anxiety Disorders And Depression Treatment Market by End User
12.1.8.2 Canada Anxiety Disorders And Depression Treatment Market
12.1.8.2.1 Canada Anxiety Disorders And Depression Treatment Market by Drug Class
12.1.8.2.2 Canada Anxiety Disorders And Depression Treatment Market by Therapies
12.1.8.2.3 Canada Anxiety Disorders And Depression Treatment Market by Devices
12.1.8.2.4 Canada Anxiety Disorders And Depression Treatment Market by Application
12.1.8.2.5 Canada Anxiety Disorders And Depression Treatment Market by End User
12.1.8.3 Mexico Anxiety Disorders And Depression Treatment Market
12.1.8.3.1 Mexico Anxiety Disorders And Depression Treatment Market by Drug Class
12.1.8.3.2 Mexico Anxiety Disorders And Depression Treatment Market by Therapies
12.1.8.3.3 Mexico Anxiety Disorders And Depression Treatment Market by Devices
12.1.8.3.4 Mexico Anxiety Disorders And Depression Treatment Market by Application
12.1.8.3.5 Mexico Anxiety Disorders And Depression Treatment Market by End User
12.2. EUROPE
12.2.1 Europe Anxiety Disorders And Depression Treatment Market Overview
12.2.2 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis
12.2.3 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Drug Class
12.2.4 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Therapies
12.2.5 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Devices
12.2.6 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Application
12.2.7 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By End User
12.2.8 Europe Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Anxiety Disorders And Depression Treatment Market
12.2.8.1.1 Germany Anxiety Disorders And Depression Treatment Market by Drug Class
12.2.8.1.2 Germany Anxiety Disorders And Depression Treatment Market by Therapies
12.2.8.1.3 Germany Anxiety Disorders And Depression Treatment Market by Devices
12.2.8.1.4 Germany Anxiety Disorders And Depression Treatment Market by Application
12.2.8.1.5 Germany Anxiety Disorders And Depression Treatment Market by End User
12.2.8.2 France Anxiety Disorders And Depression Treatment Market
12.2.8.2.1 France Anxiety Disorders And Depression Treatment Market by Drug Class
12.2.8.2.2 France Anxiety Disorders And Depression Treatment Market by Therapies
12.2.8.2.3 France Anxiety Disorders And Depression Treatment Market by Devices
12.2.8.2.4 France Anxiety Disorders And Depression Treatment Market by Application
12.2.8.2.5 France Anxiety Disorders And Depression Treatment Market by End User
12.2.8.3 Italy Anxiety Disorders And Depression Treatment Market
12.2.8.3.1 Italy Anxiety Disorders And Depression Treatment Market by Drug Class
12.2.8.3.2 Italy Anxiety Disorders And Depression Treatment Market by Therapies
12.2.8.3.3 Italy Anxiety Disorders And Depression Treatment Market by Devices
12.2.8.3.4 Italy Anxiety Disorders And Depression Treatment Market by Application
12.2.8.3.5 Italy Anxiety Disorders And Depression Treatment Market by End User
12.2.8.4 Spain Anxiety Disorders And Depression Treatment Market
12.2.8.4.1 Spain Anxiety Disorders And Depression Treatment Market by Drug Class
12.2.8.4.2 Spain Anxiety Disorders And Depression Treatment Market by Therapies
12.2.8.4.3 Spain Anxiety Disorders And Depression Treatment Market by Devices
12.2.8.4.4 Spain Anxiety Disorders And Depression Treatment Market by Application
12.2.8.4.5 Spain Anxiety Disorders And Depression Treatment Market by End User
12.2.8.5 United Kingdom Anxiety Disorders And Depression Treatment Market
12.2.8.5.1 United Kingdom Anxiety Disorders And Depression Treatment Market by Drug Class
12.2.8.5.2 United Kingdom Anxiety Disorders And Depression Treatment Market by Therapies
12.2.8.5.3 United Kingdom Anxiety Disorders And Depression Treatment Market by Devices
12.2.8.5.4 United Kingdom Anxiety Disorders And Depression Treatment Market by Application
12.2.8.5.5 United Kingdom Anxiety Disorders And Depression Treatment Market by End User
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Anxiety Disorders And Depression Treatment Market Overview
12.3.2 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis
12.3.3 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Drug Class
12.3.4 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Therapies
12.3.5 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Devices
12.3.6 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Application
12.3.7 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By End User
12.3.8 Asia-Pacific Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Anxiety Disorders And Depression Treatment Market
12.3.8.1.1 Australia Anxiety Disorders And Depression Treatment Market by Drug Class
12.3.8.1.2 Australia Anxiety Disorders And Depression Treatment Market by Therapies
12.3.8.1.3 Australia Anxiety Disorders And Depression Treatment Market by Devices
12.3.8.1.4 Australia Anxiety Disorders And Depression Treatment Market by Application
12.3.8.1.5 Australia Anxiety Disorders And Depression Treatment Market by End User
12.3.8.2 China Anxiety Disorders And Depression Treatment Market
12.3.8.2.1 China Anxiety Disorders And Depression Treatment Market by Drug Class
12.3.8.2.2 China Anxiety Disorders And Depression Treatment Market by Therapies
12.3.8.2.3 China Anxiety Disorders And Depression Treatment Market by Devices
12.3.8.2.4 China Anxiety Disorders And Depression Treatment Market by Application
12.3.8.2.5 China Anxiety Disorders And Depression Treatment Market by End User
12.3.8.3 India Anxiety Disorders And Depression Treatment Market
12.3.8.3.1 India Anxiety Disorders And Depression Treatment Market by Drug Class
12.3.8.3.2 India Anxiety Disorders And Depression Treatment Market by Therapies
12.3.8.3.3 India Anxiety Disorders And Depression Treatment Market by Devices
12.3.8.3.4 India Anxiety Disorders And Depression Treatment Market by Application
12.3.8.3.5 India Anxiety Disorders And Depression Treatment Market by End User
12.3.8.4 Japan Anxiety Disorders And Depression Treatment Market
12.3.8.4.1 Japan Anxiety Disorders And Depression Treatment Market by Drug Class
12.3.8.4.2 Japan Anxiety Disorders And Depression Treatment Market by Therapies
12.3.8.4.3 Japan Anxiety Disorders And Depression Treatment Market by Devices
12.3.8.4.4 Japan Anxiety Disorders And Depression Treatment Market by Application
12.3.8.4.5 Japan Anxiety Disorders And Depression Treatment Market by End User
12.3.8.5 South Korea Anxiety Disorders And Depression Treatment Market
12.3.8.5.1 South Korea Anxiety Disorders And Depression Treatment Market by Drug Class
12.3.8.5.2 South Korea Anxiety Disorders And Depression Treatment Market by Therapies
12.3.8.5.3 South Korea Anxiety Disorders And Depression Treatment Market by Devices
12.3.8.5.4 South Korea Anxiety Disorders And Depression Treatment Market by Application
12.3.8.5.5 South Korea Anxiety Disorders And Depression Treatment Market by End User
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Anxiety Disorders And Depression Treatment Market Overview
12.4.2 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis
12.4.3 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Drug Class
12.4.4 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Therapies
12.4.5 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Devices
12.4.6 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Application
12.4.7 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By End User
12.4.8 Middle East and Africa Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Anxiety Disorders And Depression Treatment Market
12.4.8.1.1 South Africa Anxiety Disorders And Depression Treatment Market by Drug Class
12.4.8.1.2 South Africa Anxiety Disorders And Depression Treatment Market by Therapies
12.4.8.1.3 South Africa Anxiety Disorders And Depression Treatment Market by Devices
12.4.8.1.4 South Africa Anxiety Disorders And Depression Treatment Market by Application
12.4.8.1.5 South Africa Anxiety Disorders And Depression Treatment Market by End User
12.4.8.2 Saudi Arabia Anxiety Disorders And Depression Treatment Market
12.4.8.2.1 Saudi Arabia Anxiety Disorders And Depression Treatment Market by Drug Class
12.4.8.2.2 Saudi Arabia Anxiety Disorders And Depression Treatment Market by Therapies
12.4.8.2.3 Saudi Arabia Anxiety Disorders And Depression Treatment Market by Devices
12.4.8.2.4 Saudi Arabia Anxiety Disorders And Depression Treatment Market by Application
12.4.8.2.5 Saudi Arabia Anxiety Disorders And Depression Treatment Market by End User
12.4.8.3 U.A.E Anxiety Disorders And Depression Treatment Market
12.4.8.3.1 U.A.E Anxiety Disorders And Depression Treatment Market by Drug Class
12.4.8.3.2 U.A.E Anxiety Disorders And Depression Treatment Market by Therapies
12.4.8.3.3 U.A.E Anxiety Disorders And Depression Treatment Market by Devices
12.4.8.3.4 U.A.E Anxiety Disorders And Depression Treatment Market by Application
12.4.8.3.5 U.A.E Anxiety Disorders And Depression Treatment Market by End User
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Anxiety Disorders And Depression Treatment Market Overview
12.5.2 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis
12.5.3 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Drug Class
12.5.4 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Therapies
12.5.5 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Devices
12.5.6 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Application
12.5.7 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By End User
12.5.8 South and Central America Anxiety Disorders And Depression Treatment Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Anxiety Disorders And Depression Treatment Market
12.5.8.1.1 Brazil Anxiety Disorders And Depression Treatment Market by Drug Class
12.5.8.1.2 Brazil Anxiety Disorders And Depression Treatment Market by Therapies
12.5.8.1.3 Brazil Anxiety Disorders And Depression Treatment Market by Devices
12.5.8.1.4 Brazil Anxiety Disorders And Depression Treatment Market by Application
12.5.8.1.5 Brazil Anxiety Disorders And Depression Treatment Market by End User
12.5.8.2 Argentina Anxiety Disorders And Depression Treatment Market
12.5.8.2.1 Argentina Anxiety Disorders And Depression Treatment Market by Drug Class
12.5.8.2.2 Argentina Anxiety Disorders And Depression Treatment Market by Therapies
12.5.8.2.3 Argentina Anxiety Disorders And Depression Treatment Market by Devices
12.5.8.2.4 Argentina Anxiety Disorders And Depression Treatment Market by Application
12.5.8.2.5 Argentina Anxiety Disorders And Depression Treatment Market by End User
12.5.8.3 Chile Anxiety Disorders And Depression Treatment Market
12.5.8.3.1 Chile Anxiety Disorders And Depression Treatment Market by Drug Class
12.5.8.3.2 Chile Anxiety Disorders And Depression Treatment Market by Therapies
12.5.8.3.3 Chile Anxiety Disorders And Depression Treatment Market by Devices
12.5.8.3.4 Chile Anxiety Disorders And Depression Treatment Market by Application
12.5.8.3.5 Chile Anxiety Disorders And Depression Treatment Market by End User

13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

14. ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET, KEY COMPANY PROFILES
14.1. SUMITOMO DAINIPPON PHARMA CO.
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. SAGE THERAPEUTICS
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. GLAXOSMITHKLINE PLC
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. F. HOFFMANN-LA ROCHE LTD
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. ELI LILLY AND COMPANY
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. ABBOTT
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. SANOFI
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. H. LUNDBECK A/S
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. JOHNSON AND JOHNSON
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments

15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
The List of Companies

1. Sumitomo Dainippon Pharma Co.
2. Sage Therapeutics
3. GlaxoSmithKline plc
4. F. Hoffmann-La Roche Ltd
5. Eli Lilly and Company
6. Abbott
7. Sanofi
8. H. Lundbeck A/S
TIPRE00008009
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking